Bernstein analyst Miki Sogi initiated coverage of Otsuka (OTSKY) with a Market Perform rating. The firm believes the current stock price ...

Citing the Tokyo-based firm’s earnings results on Friday, Evercore ISI analyst Liisa Bayko argued that Otsuka’s (OTCPK:OTSKY) sibeprenlimab, which rivals Vera’s (NASDAQ:VERA) atacicept in ...

Ionis (IONS) out-licenses the rights for its HAE drug to Otsuka in the Asia-Pacific region. The companies signed a similar deal last year granting Otsuka rights to market the drug in Europe.

1 Day OTSKY 1.04% DJIA 0.30% S&P 500 0.72% Health Care/Life Sciences 0.47% ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.